Revista nº 817

Profilaxis de angioedemas hereditarios | Rodríguez Bote MD, et al. 188 Actual Med.2023;108(817):185-188 6. Weller K, Maurer M, Fridman M, Supina D, Schranz J, Ma- gerl M. Health-related quality of life with hereditary an- gioedema following prophylaxis with subcutaneous C1-in- hibitor with recombinant hyaluronidase. Allergy Asthma Proc. 2017;38(2):143-51. DOI: 10.2500/aap.2017.38.4025 7. Bernstein JA, Li HH, Craig TJ, Manning ME, Lawo JP, Ma- chnig T, et al. Indirect comparison of intravenous vs. sub- cutaneous C1-inhibitor placebo-controlled trials for rou- tine prevention of hereditary angioedema attacks. Aller- gy Asthma Clin Immunol. 2019;15(1):1-9. DOI: 10.1186/ s13223-019-0328-3 8. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 pa- tients. Ann Allergy Asthma Immunol. 2008;100(2):153-61. DOI: 10.1016/S1081-1206(10)60424-3. 9. Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for in- dividual replacement therapy in patients with severe he- reditary angioedema refractory to danazol prophylaxis. Transfusion. 2009;49(9):1987-95. DOI: 10.1111/j.1537- 2995.2009.02230.x Si desea citar nuestro artículo: Rodríguez Bote MD, Fernández Delgado L, Conde Alcañiz A, Guar- dia Martínez P. Actualización en la profilaxis a largo plazo en los angioedemas hereditarios con C1 inhibidor disminuido. Actual Med.2023;108(817):185-188. DOI:10.15568/am.2023.817.cc01